デフォルト表紙
市場調査レポート
商品コード
1427879

がん診断向けリキッドバイオプシーの世界市場レポート2024

Liquid Biopsy For Cancer Diagnostics Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
がん診断向けリキッドバイオプシーの世界市場レポート2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

がん診断向けリキッドバイオプシーの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には15.7%の年間複合成長率(CAGR)で164億2,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、日常的ながん診断へのリキッドバイオプシーの組み込み、がんの早期発見のためのリキッドバイオプシーの普及、がんスクリーニングプログラムの拡大、腫瘍学における個別化医療への重点の増加、および医療システムの強化によってもたらされると予想されます。リキッドバイオプシー調査への資金提供。予測期間における注目すべき動向には、マルチオミックスリキッドバイオプシーアプローチの台頭、リキッドバイオプシー分析への人工知能の統合、腫瘍学を超えたリキッドバイオプシーアプリケーションの拡張、がんの血液ベースのバイオマーカーの開発、および特定の種類のがんに対するリキッドバイオプシーアッセイ。

がん罹患率の予測増加は、将来のがん診断向けリキッドバイオプシー市場の拡大を促進すると予想されます。がんは、さまざまな器官や組織に現れる幅広い病気を含み、正常な境界を突破する異常な細胞の制御されない増殖によって生じ、他の器官に転移したり、隣接する身体部分に侵入したりする可能性があります。がんの有病率が高まっているため、がんや腫瘍の再発の早期発見、個別のリスク評価、継続的な治療モニタリングなどの診断手順が必要となります。リキッドバイオプシーは極めて重要なツールとして台頭しており、転移部位または原発腫瘍部位から腫瘍細胞またはその生成物を捕捉することで、疾患に関する包括的かつリアルタイムの洞察を提供します。この方法は、腫瘍細胞の進化、治療標的、および治療抵抗性のメカニズムに関する貴重な情報を提供します。 2021年、米国がん協会は、2020年に新たにがんと診断された患者数が180万人だったと報告しました。さらに、国立がん研究所が発表した2020年9月のデータは、米国の新規がん患者数が大幅に増加し、2020年には1,806,590人に達し、過去43年間で43万人を記録しました。前年と比較して、男性で診断された症例の%増加。

個別化医療に対する需要の高まりにより、がん診断向けリキッドバイオプシー市場の発展が促進される見込みです。個別化医療は、患者の遺伝子、環境、ライフスタイルにおける個人差を考慮した革新的なヘルスケアアプローチを表します。リキッドバイオプシーは、がんに関連する特定の遺伝子変異やバイオマーカーを特定する上で重要な役割を果たし、目的に合わせた標的治療戦略の開発を促進します。特に、2022年に個別化医療連合は、2021年に新たに承認された新規分子実体(NME)の35%が個別化医療であると報告しました。この個別化医療の需要の急増は、予見可能な範囲でバイオインフォマティクスサービス市場の成長を促進すると予想されています未来。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 市場セグメンテーション

  • 世界のがん診断向けリキッドバイオプシー市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 製品
  • サービス
  • 世界のがん診断向けリキッドバイオプシー市場、サンプル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 血液
  • 尿
  • 唾液
  • 世界のがん診断向けリキッドバイオプシー市場、がん別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 肺がん
  • 乳がん
  • 結腸がん
  • その他のがん
  • 世界のがん診断向けリキッドバイオプシー市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 診断センター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のがん診断向けリキッドバイオプシー市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のがん診断向けリキッドバイオプシー市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • がん診断向けリキッドバイオプシー市場の競合情勢
  • がん診断市場向けリキッドバイオプシー企業プロファイル
    • F. Hoffman La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies Inc.
    • Illumina Inc.
    • The Menarini Group

第31章 その他の大手および革新的な企業

  • Bio-Rad Laboratories Inc.
  • QIAGEN Inc.
  • Exact Sciences Corporation
  • Bio-Techne Corporation
  • ArcherDX Inc.
  • Neogenomics Laboratories Inc.
  • Guardant Health Inc.
  • Myriad Genetics Inc.
  • Foundation Medicine Inc.
  • Amoy Diagnostics Co. Ltd.
  • Biocartis Group NV
  • Biodesix Inc.
  • MDx Health Inc.
  • Sysmex Inostics Inc.
  • Biocept Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13723

Liquid biopsy for cancer diagnostics offers a less invasive alternative to traditional tissue biopsies, involving the assessment of genetic material or biomarkers found in a patient's blood or other bodily fluids to detect and monitor the presence of cancer. This approach is commonly utilized for screening and identifying non-small cell lung cancer (NSCLC) and is also employed as a gastrointestinal and ovarian liquid biopsy for cancer diagnostics.

The main categories within liquid biopsy for cancer diagnostics encompass products and services. Products refer to procedures, methods, or tools designed or utilized for identifying illnesses or diseases in humans or other vertebrate animals. Various types of samples, such as blood, urine, and saliva, are utilized in this diagnostic approach. Liquid biopsy for cancer diagnostics is applicable to various types of cancer, including lung cancer, breast cancer, colon cancer, and others. The end-users for these diagnostics include hospitals, diagnostic centers, and other healthcare institutions.

The liquid biopsy for cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides liquid biopsy for cancer diagnostics market statistics, including liquid biopsy for cancer diagnostics industry global market size, regional shares, competitors with a liquid biopsy for cancer diagnostics market share, detailed liquid biopsy for cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy for cancer diagnostics industry. This liquid biopsy for cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liquid biopsy for cancer diagnostics market size has grown rapidly in recent years. It will grow from $7.82 billion in 2023 to $9.17 billion in 2024 at a compound annual growth rate (CAGR) of 17.3%. The growth experienced in the past can be ascribed to progress in genomic research, heightened recognition of the advantages of liquid biopsy, a surge in cancer prevalence, an uptick in the demand for non-invasive cancer testing, and the expansion of precision medicine initiatives.

The liquid biopsy for cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $16.42 billion in 2028 at a compound annual growth rate (CAGR) of 15.7%. Anticipated growth during the forecast period is expected to result from the incorporation of liquid biopsy into routine cancer diagnostics, the widespread adoption of liquid biopsy for early cancer detection, the expansion of cancer screening programs, an increased emphasis on personalized medicine in oncology, and augmented funding for liquid biopsy research. Noteworthy trends in the forecast period encompass the rise of multi-omics liquid biopsy approaches, the integration of artificial intelligence into liquid biopsy analysis, the extension of liquid biopsy applications beyond oncology, the development of blood-based biomarkers for cancer, and the tailoring of liquid biopsy assays for specific cancer types.

The projected increase in cancer incidence is anticipated to drive the expansion of the liquid biopsy for cancer diagnostics market in the future. Cancer, encompassing a wide range of illnesses that can manifest in various organs or tissues, results from the uncontrolled proliferation of aberrant cells that breach normal boundaries, potentially spreading to other organs or invading adjacent body parts. The heightened prevalence of cancer necessitates diagnostic procedures, including early cancer or tumor recurrence detection, individualized risk assessment, and ongoing therapy monitoring. Liquid biopsy emerges as a pivotal tool, offering comprehensive and real-time insights into the disease by capturing tumor cells or their products from metastatic or primary tumor sites. This method provides valuable information on tumor cell evolution, therapeutic targets, and mechanisms of therapy resistance. In 2021, the American Cancer Society reported 1.8 million new cancer cases diagnosed in 2020. Additionally, data from September 2020 published by the National Cancer Institute indicated a significant increase in new cancer cases in the United States, reaching 1,806,590 in 2020, marking a 43% rise in cases diagnosed in men compared to the previous year.

The growing demand for personalized medicine is poised to fuel the advancement of the liquid biopsy for cancer diagnostics market. Personalized medicine represents an innovative healthcare approach that considers individual variabilities in patients' genes, environments, and lifestyles. Liquid biopsy plays a crucial role in identifying specific genetic mutations and biomarkers associated with cancer, facilitating the development of tailored and targeted treatment strategies. Notably, in 2022, the Personalized Medicine Coalition reported that personalized medicines accounted for 35% of newly approved new molecular entities (NMEs) in 2021. This surge in demand for personalized medicine is expected to drive the growth of the bioinformatics services market in the foreseeable future.

A prominent trend gaining traction is the focus on product innovations by major companies. These companies are strategically investing in the development of cutting-edge products to bolster their market position. An exemplar of this trend is BostonGene, a US-based biomedical software company, which introduced new liquid biopsy solutions in June 2023. These solutions aim to identify clinically relevant gene alterations, expanding the test portfolio and accelerating the development of novel assays, analytical tools, and pipelines. The innovative approach involves leveraging artificial intelligence-driven molecular and immunological profiling methodologies to analyze tumors, microenvironments, and host immunity. Notably, these solutions support immunotherapy treatment, provide insights into a patient's immune-related disorders, and enable the monitoring of disease progression and response to treatment.

Major players in the liquid biopsy for cancer diagnostics market are directing their efforts toward the development of advanced liquid biopsy assays. These assays, characterized by sophistication and refinement, analyze various components within liquid biological samples, such as blood or other bodily fluids. The objective is to detect and characterize specific biomarkers associated with cancer or other diseases. Illumina Inc., a global leader in DNA sequencing, exemplifies this focus on innovation. In November 2023, the company announced the launch of the 'TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)' research assay. This assay facilitates noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) extracted from blood. Designed to streamline integration for users, the TSO 500 ctDNA v2 assay enhances the depth of insights available for cancer research.

In January 2022, when Exact Sciences Corp., a US-based molecular diagnostics company, acquired Thrive Earlier Detection Corp. for $2.15 billion. This strategic acquisition positions Exact Sciences Corp. to access clinical and regulatory teams, scale laboratory and IT capabilities, and advance blood-based, multi-cancer screening, aligning with evolving norms in cancer treatment. Thrive Earlier Detection Corp., known for its expertise in producing liquid biopsy tests, focuses on the early detection of multiple cancers.

Major companies operating in the liquid biopsy for cancer diagnostics market report are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC

North America was the largest region in the liquid biopsy for cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the liquid biopsy for cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liquid biopsy for cancer diagnostics market includes revenues earned by entities by providing tumor detection, test validation, and clinical utility. The market value includes the value of related goods sold by the service provider or included within the service offering. The liquid biopsy for cancer diagnostics markets also include sales of instruments, reagent kits, and liquid biopsy kits, which are used in providing liquid biopsy services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Liquid Biopsy For Cancer Diagnostics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on liquid biopsy for cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for liquid biopsy for cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liquid biopsy for cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Product; Services
  • 2) By Sample: Blood; Urine; Saliva
  • 3) By Cancer: Lung Cancer; Breast Cancer; Colon Cancer; Other Cancers
  • 4) By End-User: Hospitals; Diagnostic Centers; Other End-Users
  • Companies Mentioned: F. Hoffman La Roche Ltd.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Illumina Inc.; The Menarini Group
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Liquid Biopsy For Cancer Diagnostics Market Characteristics

3. Liquid Biopsy For Cancer Diagnostics Market Trends And Strategies

4. Liquid Biopsy For Cancer Diagnostics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Liquid Biopsy For Cancer Diagnostics Market Size and Growth

  • 5.1. Global Liquid Biopsy For Cancer Diagnostics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Liquid Biopsy For Cancer Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Liquid Biopsy For Cancer Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Liquid Biopsy For Cancer Diagnostics Market Segmentation

  • 6.1. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Product
  • Services
  • 6.2. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Sample, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Blood
  • Urine
  • Saliva
  • 6.3. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lung Cancer
  • Breast Cancer
  • Colon Cancer
  • Other Cancers
  • 6.4. Global Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Diagnostic Centers
  • Other End-Users

7. Liquid Biopsy For Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Liquid Biopsy For Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Liquid Biopsy For Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market

  • 8.1. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Liquid Biopsy For Cancer Diagnostics Market

  • 9.1. China Liquid Biopsy For Cancer Diagnostics Market Overview
  • 9.2. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Liquid Biopsy For Cancer Diagnostics Market

  • 10.1. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Liquid Biopsy For Cancer Diagnostics Market

  • 11.1. Japan Liquid Biopsy For Cancer Diagnostics Market Overview
  • 11.2. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Liquid Biopsy For Cancer Diagnostics Market

  • 12.1. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Liquid Biopsy For Cancer Diagnostics Market

  • 13.1. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Liquid Biopsy For Cancer Diagnostics Market

  • 14.1. South Korea Liquid Biopsy For Cancer Diagnostics Market Overview
  • 14.2. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Liquid Biopsy For Cancer Diagnostics Market

  • 15.1. Western Europe Liquid Biopsy For Cancer Diagnostics Market Overview
  • 15.2. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Liquid Biopsy For Cancer Diagnostics Market

  • 16.1. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Liquid Biopsy For Cancer Diagnostics Market

  • 17.1. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Liquid Biopsy For Cancer Diagnostics Market

  • 18.1. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Liquid Biopsy For Cancer Diagnostics Market

  • 19.1. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Liquid Biopsy For Cancer Diagnostics Market

  • 20.1. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market

  • 21.1. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Liquid Biopsy For Cancer Diagnostics Market

  • 22.1. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Liquid Biopsy For Cancer Diagnostics Market

  • 23.1. North America Liquid Biopsy For Cancer Diagnostics Market Overview
  • 23.2. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Liquid Biopsy For Cancer Diagnostics Market

  • 24.1. USA Liquid Biopsy For Cancer Diagnostics Market Overview
  • 24.2. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Liquid Biopsy For Cancer Diagnostics Market

  • 25.1. Canada Liquid Biopsy For Cancer Diagnostics Market Overview
  • 25.2. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Liquid Biopsy For Cancer Diagnostics Market

  • 26.1. South America Liquid Biopsy For Cancer Diagnostics Market Overview
  • 26.2. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Liquid Biopsy For Cancer Diagnostics Market

  • 27.1. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Liquid Biopsy For Cancer Diagnostics Market

  • 28.1. Middle East Liquid Biopsy For Cancer Diagnostics Market Overview
  • 28.2. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Liquid Biopsy For Cancer Diagnostics Market

  • 29.1. Africa Liquid Biopsy For Cancer Diagnostics Market Overview
  • 29.2. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Liquid Biopsy For Cancer Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Liquid Biopsy For Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Liquid Biopsy For Cancer Diagnostics Market Competitive Landscape
  • 30.2. Liquid Biopsy For Cancer Diagnostics Market Company Profiles
    • 30.2.1. F. Hoffman La Roche Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Thermo Fisher Scientific Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Agilent Technologies Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Illumina Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. The Menarini Group
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Liquid Biopsy For Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. Bio-Rad Laboratories Inc.
  • 31.2. QIAGEN Inc.
  • 31.3. Exact Sciences Corporation
  • 31.4. Bio-Techne Corporation
  • 31.5. ArcherDX Inc.
  • 31.6. Neogenomics Laboratories Inc.
  • 31.7. Guardant Health Inc.
  • 31.8. Myriad Genetics Inc.
  • 31.9. Foundation Medicine Inc.
  • 31.10. Amoy Diagnostics Co. Ltd.
  • 31.11. Biocartis Group NV
  • 31.12. Biodesix Inc.
  • 31.13. MDx Health Inc.
  • 31.14. Sysmex Inostics Inc.
  • 31.15. Biocept Inc.

32. Global Liquid Biopsy For Cancer Diagnostics Market Competitive Benchmarking

33. Global Liquid Biopsy For Cancer Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Liquid Biopsy For Cancer Diagnostics Market

35. Liquid Biopsy For Cancer Diagnostics Market Future Outlook and Potential Analysis

  • 35.1 Liquid Biopsy For Cancer Diagnostics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Liquid Biopsy For Cancer Diagnostics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Liquid Biopsy For Cancer Diagnostics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer